Psychiatric and cognitive correlates of quality of life among persons with primary brain tumors.
Anxiety
Mini-Mental State Examination
brain tumors
depression
quality of life
tumor laterality
Journal
Industrial psychiatry journal
ISSN: 0972-6748
Titre abrégé: Ind Psychiatry J
Pays: India
ID NLM: 101547239
Informations de publication
Date de publication:
Historique:
received:
03
08
2019
revised:
12
10
2019
accepted:
18
11
2019
entrez:
28
12
2019
pubmed:
28
12
2019
medline:
28
12
2019
Statut:
ppublish
Résumé
Quality of life (QoL) in primary brain tumour (PBT) is often the main outcome measure in an otherwise incurable disease. The impact of psychiatric, cognitive correlates on quality of life in primary brain tumours is less well studied. The primary objective was to find out the association of psychiatric morbidity, cognitive functions with quality of life in patients with primary brain tumours. The secondary objective was to study whether any association exists with tumour grading, laterality, location and psychiatric morbidity. 100 consecutive patients of PBT were screened in the Neuro-behavioural Clinic. Age, gender matched 52 healthy subjects were taken for comparison. Quality of life (qol) measure (EORTC), Hospital Anxiety Depression Scale (HADS), GHQ (12 item) and Mini Mental State Examination (MMSE) were administered. 52 PBT cases were included, out of which 17.30% had Organic Anxiety Disorder (F06.4), 23.07% had Organic Mood disorder (F06.3%).Statistically significant association was found in EORTC qol scores and anxiety scores (p 0.001), depressive scores (p 0.029), psychiatric morbidity (p0.000) .Significant association with tumour laterality, depression scores (p0.041) was found. PBT patients had poor quality of life as compared to matched healthy volunteers (p <0.001). Significant negative correlation between EORTC B-20, cognitive scores using Spearman's Rho (p0.005; r - 0.385), implying more symptoms with poor cognitive function scores. Psychiatric morbidity, cognitive dysfunction, poor qol were noted, though no association with tumour grading, location. Regular assessments, early intervention will help in improving quality of life in PBT.
Sections du résumé
BACKGROUND
BACKGROUND
Quality of life (QoL) in primary brain tumour (PBT) is often the main outcome measure in an otherwise incurable disease. The impact of psychiatric, cognitive correlates on quality of life in primary brain tumours is less well studied.
AIMS AND OBJECTIVES
OBJECTIVE
The primary objective was to find out the association of psychiatric morbidity, cognitive functions with quality of life in patients with primary brain tumours. The secondary objective was to study whether any association exists with tumour grading, laterality, location and psychiatric morbidity.
MATERIALS AND METHODS
METHODS
100 consecutive patients of PBT were screened in the Neuro-behavioural Clinic. Age, gender matched 52 healthy subjects were taken for comparison. Quality of life (qol) measure (EORTC), Hospital Anxiety Depression Scale (HADS), GHQ (12 item) and Mini Mental State Examination (MMSE) were administered.
RESULTS
RESULTS
52 PBT cases were included, out of which 17.30% had Organic Anxiety Disorder (F06.4), 23.07% had Organic Mood disorder (F06.3%).Statistically significant association was found in EORTC qol scores and anxiety scores (p 0.001), depressive scores (p 0.029), psychiatric morbidity (p0.000) .Significant association with tumour laterality, depression scores (p0.041) was found. PBT patients had poor quality of life as compared to matched healthy volunteers (p <0.001). Significant negative correlation between EORTC B-20, cognitive scores using Spearman's Rho (p0.005; r - 0.385), implying more symptoms with poor cognitive function scores. Psychiatric morbidity, cognitive dysfunction, poor qol were noted, though no association with tumour grading, location.
CONCLUSION
CONCLUSIONS
Regular assessments, early intervention will help in improving quality of life in PBT.
Identifiants
pubmed: 31879461
doi: 10.4103/ipj.ipj_72_19
pii: IPJ-28-141
pmc: PMC6929219
doi:
Types de publication
Journal Article
Langues
eng
Pagination
141-147Informations de copyright
Copyright: © 2019 Industrial Psychiatry Journal.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Neuro Oncol. 2000 Oct;2(4):221-8
pubmed: 11265231
J Neurooncol. 2017 Jan;131(2):413-419
pubmed: 27900643
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Neuro Oncol. 2015 Jun;17(6):776-83
pubmed: 25313193
Oncologist. 2010;15(6):618-26
pubmed: 20507891
Zh Vopr Neirokhir Im N N Burdenko. 2010 Jul-Sep;(3):25-31; discussion 31
pubmed: 21254573
World Neurosurg. 2018 Apr;112:64-72
pubmed: 29360583
J Cancer Res Ther. 2018 Dec;14(Supplement):S1048-S1051
pubmed: 30539844
J Neurol Neurosurg Psychiatry. 2003 Sep;74(9):1278-82
pubmed: 12933936
J Neurosurg. 2019 Jan 11;:1-8
pubmed: 30641847
Qual Life Res. 2016 Sep;25(9):2245-56
pubmed: 27039304
Lancet. 2018 Aug 4;392(10145):432-446
pubmed: 30060998
J Neurosurg. 2003 Jan;98(1):21-31
pubmed: 12546348
Indian J Cancer. 2015 Oct-Dec;52(4):580-5
pubmed: 26960484
Psychooncology. 2019 Jan;28(1):11-21
pubmed: 30280453
Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):59-64
pubmed: 10924972
J Neurosurg. 2008 Feb;108(2):281-6
pubmed: 18240923
Neuro Oncol. 2013 Jan;15(1):122-9
pubmed: 23229997
Neuro Oncol. 2009 Jun;11(3):330-9
pubmed: 19001097
Oncotarget. 2017 Aug 3;8(55):94932-94943
pubmed: 29212279
World Neurosurg. 2018 Sep;117:e465-e474
pubmed: 29920391
J Cancer Res Ther. 2006 Oct-Dec;2(4):166-70
pubmed: 17998699
Neuro Oncol. 2008 Apr;10(2):171-81
pubmed: 18314416
Health Qual Life Outcomes. 2003 Aug 01;1:29
pubmed: 12914662
Acta Neurochir (Wien). 2014 Feb;156(2):367-74
pubmed: 24254135
Oncotarget. 2017 Feb 25;8(34):57543-57551
pubmed: 28915694
World J Psychiatry. 2015 Sep 22;5(3):273-85
pubmed: 26425442
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Arch Neurol. 1999 Apr;56(4):401-4
pubmed: 10199326
Neuro Oncol. 2016 Nov;18(11):1475-1486
pubmed: 27194147
Neuropsychiatr Dis Treat. 2015 Jun 10;11:1413-20
pubmed: 26089669
J Neurosurg Sci. 2013 Sep;57(3):259-66
pubmed: 23877271
Clin Neurol Neurosurg. 2018 Sep;172:8-19
pubmed: 29957299